{"product_id":"crnx-vrio-analysis","title":"Crinetics Pharmaceuticals, Inc. (CRNX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Crinetics Pharmaceuticals, Inc. (CRNX) truly built to last? This VRIO analysis strips away the hype, rigorously testing its core assets for Value, Rarity, Inimitability, and Organization to pinpoint exactly where its competitive edge lies. Dive in below to uncover the strategic strengths that secure its market position - and the crucial areas that might be holding it back.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 1. U.S. FDA-Approved Oral Therapy for Acromegaly (PALSONIFY™\/Paltusotine)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’ve just crossed the finish line with PALSONIFY (paltusotine), moving Crinetics Pharmaceuticals from a clinical-stage outfit to a revenue-generating entity with the U.S. FDA approval on \u003cstrong\u003eSeptember 25, 2025\u003c\/strong\u003e. This is a massive shift, and now we need to look at what this asset actually means for sustained competitive positioning.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Establishing a Commercial Footprint\u003c\/h3\u003e\n\u003cp\u003eThe value here is twofold: immediate, albeit small, revenue for the 2025 fiscal year, and the establishment of Crinetics as a commercial-stage company. Consensus forecasts point to total company revenue hitting about \u003cstrong\u003e$5.1 million\u003c\/strong\u003e for 2025, with PALSONIFY providing \u003cstrong\u003e96%\u003c\/strong\u003e of that figure, which is a strong indicator of its immediate importance. But the real value is the paradigm shift - it’s the first once-daily, oral therapy for acromegaly. This convenience directly challenges established injectables like Novartis AG’s Sandostatin, which analysts forecast still bringing in \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e in 2025 sales. PALSONIFY’s oral nature is the key value driver that should erode that market share over time.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the competitive set:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct\/Company\u003c\/td\u003e\n    \u003ctd\u003e2025 Sales Forecast (USD)\u003c\/td\u003e\n    \u003ctd\u003eDelivery Method\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePALSONIFY (CRNX)\u003c\/td\u003e\n    \u003ctd\u003e~\u003cstrong\u003e$4.9 million\u003c\/strong\u003e (96% of $5.1M)\u003c\/td\u003e\n    \u003ctd\u003eOral\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSandostatin (Novartis AG)\u003c\/td\u003e\n    \u003ctd\u003e~\u003cstrong\u003e$1.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eInjectable\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSomatuline (Ipsen SA)\u003c\/td\u003e\n    \u003ctd\u003e~\u003cstrong\u003e$557 million\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eInjectable\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity: A First-in-Class Oral Option\u003c\/h3\u003e\n\u003cp\u003eHaving the first-in-class oral treatment for a major endocrine indication like acromegaly is inherently rare, especially for a company of Crinetics’ prior scale. The existing standard of care relies on injectables, which means this oral option is genuinely unique in the market right now. It’s rare because it was developed in-house, representing a novel nonpeptide SST2 agonist. This scarcity gives them a clear, immediate advantage in physician and patient preference.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Patent Protection vs. Target Knowledge\u003c\/h3\u003e\n\u003cp\u003eImitability is where things get interesting, though the patent life offers a solid shield. The specific molecule and its clinical data are protected by U.S. patents issued out to \u003cstrong\u003e2037\u003c\/strong\u003e. That’s a long runway, defintely. However, the concept of an oral somatostatin receptor type 2 (SST2) agonist is now a known target, meaning competitors will definitely be trying to develop next-generation molecules. The high barrier is the molecule itself and the successful Phase 3 data package, not just the therapeutic idea.\u003c\/p\u003e\n\u003cp\u003eKey barriers to imitation include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eProprietary molecule structure.\u003c\/li\u003e\n  \u003cli\u003eSuccessful Phase 3 trial execution.\u003c\/li\u003e\n  \u003cli\u003ePatent protection extending to \u003cstrong\u003e2037\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization: Executing the Commercial Build-Out\u003c\/h3\u003e\n\u003cp\u003eThe organization scores high because the team executed a seamless launch; healthcare providers were writing prescriptions immediately following the \u003cstrong\u003eSeptember 25, 2025\u003c\/strong\u003e approval. This suggests commercial readiness was in place. Selling, general and administrative expenses jumped to \u003cstrong\u003e$52.3 million\u003c\/strong\u003e in the third quarter of 2025, largely to support this launch. Furthermore, the company’s financial structure supports this transition, with cash, cash equivalents, and investments totaling \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e as of September 30, 2025, projecting a cash runway into \u003cstrong\u003e2029\u003c\/strong\u003e. If onboarding takes 14+ days, churn risk rises, but early feedback suggests a good start. This infrastructure is organized to support the product.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Scoring\u003c\/h3\u003e\n\u003cp\u003eBased on the VRIO assessment, PALSONIFY currently grants Crinetics a \u003cstrong\u003eTemporary Competitive Advantage\u003c\/strong\u003e. The first-mover advantage from being the first oral therapy is strong, but the patent life provides a necessary buffer against direct imitation. The organization is clearly set up to capitalize on this window.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eImplication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eCreates revenue and commercial status\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eFirst-in-class oral therapy\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eCostly\/Difficult (Patented to \u003cstrong\u003e2037\u003c\/strong\u003e)\u003c\/td\u003e\n    \u003ctd\u003eProtected, but the target is known\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eSeamless launch execution and financial runway\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eStrong first-mover advantage buffered by patents\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 2. Robust Financial Position (Cash Runway into 2029)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Funds aggressive R\u0026amp;D and commercial build-out without immediate dilution risk. Cash, cash equivalents, and investments totaled \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e as of September 30, 2025, providing runway into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount as of September 30, 2025\u003c\/th\u003e\n\u003cth\u003eAmount as of December 31, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments (Total)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$110,901 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$264,545 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestment Securities (Amortized Cost)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$979,147 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,088,561 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated 2025 Cash Used in Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$340 and $370 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs have strong cash positions, but a runway extending past \u003cstrong\u003e2028\u003c\/strong\u003e is significant for a company with multiple late-stage assets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and investments were \u003cstrong\u003e$1.3 billion\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and investments were \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can raise capital, but this specific balance sheet strength is unique to their prior financing and partnership deals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFinancing included gross proceeds of \u003cstrong\u003e$350 million\u003c\/strong\u003e from a February 2024 private placement equity financing and \u003cstrong\u003e$575 million\u003c\/strong\u003e from an October 2024 public offering.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management explicitly states they are funded to execute their operating plan, showing clear financial stewardship.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This financial cushion allows for strategic, unhurried execution across the pipeline.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 3. Deep, Endocrine-Focused Pipeline (10+ Programs)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies risk away from a single asset and provides multiple future value creation opportunities in specialized markets. The company is advancing five clinical trials across its pipeline as of November 2025. The lead candidate, Paltusotine, has peak sales projections between $1.2–$1.8 billion.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs have pipelines, but this depth, focused entirely on endocrine diseases, is specialized. The pipeline includes candidates across multiple distinct endocrine pathways and diseases.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Building a pipeline of this breadth takes years of dedicated, specialized R\u0026amp;D investment. Research and development expenses were $76.2 million for the three months ended March 31, 2025, and $90.5 million for the quarter ended September 30, 2025, demonstrating significant, sustained investment in internal discovery efforts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company is actively advancing five clinical trials across the pipeline, showing organizational capacity to manage complexity. The company had 437 employees as of October 2025. As of September 30, 2025, cash, cash equivalents, and investments totaled $1.1 billion, anticipated to provide runway into 2029.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The sheer volume of specialized, internally-discovered assets is hard to replicate quickly. The company has 24 clinical trials associated with its pipeline listed in one source.\u003c\/p\u003e\n\u003cp\u003eThe depth of the pipeline is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram\u003c\/td\u003e\n\u003ctd\u003eIndication(s) Focus\u003c\/td\u003e\n\u003ctd\u003ePlatform\/Status Highlight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePaltusotine (PALSONIFY™)\u003c\/td\u003e\n\u003ctd\u003eAcromegaly, Carcinoid Syndrome (NETs)\u003c\/td\u003e\n\u003ctd\u003eApproved in U.S. for Acromegaly; Phase 3 for Carcinoid Syndrome\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtumelnant\u003c\/td\u003e\n\u003ctd\u003eClassic Congenital Adrenal Hyperplasia (CAH), ACTH-dependent Cushing's syndrome (ADCS)\u003c\/td\u003e\n\u003ctd\u003eOral MC2R Receptor Antagonist; Planned Phase 3 trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRN09682\u003c\/td\u003e\n\u003ctd\u003eSST2-expressing Neuroendocrine Tumors (NETs) and other solid tumors\u003c\/td\u003e\n\u003ctd\u003eNon-peptide Drug Conjugate; Phase 1\/2 trial anticipated to begin enrollment in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTSH Antagonist\u003c\/td\u003e\n\u003ctd\u003eGraves' hyperthyroidism, Thyroid Eye Disease (TED)\u003c\/td\u003e\n\u003ctd\u003eIND-enabling studies\/Alternative candidate being brought forward\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSST3 Agonist\u003c\/td\u003e\n\u003ctd\u003eAutosomal Dominant Polycystic Kidney Disease (ADPKD)\u003c\/td\u003e\n\u003ctd\u003eIND-enabling studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePTH Antagonist\u003c\/td\u003e\n\u003ctd\u003eHyperparathyroidism\u003c\/td\u003e\n\u003ctd\u003eIND-enabling studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional pipeline components include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOral GLP Nonpeptide for Diabetes, Obesity.\u003c\/li\u003e\n\u003cli\u003eOral GIP Nonpeptide for Diabetes, Obesity.\u003c\/li\u003e\n\u003cli\u003eInvestment in Radionetics for targeted radiotherapy.\u003c\/li\u003e\n\u003cli\u003ePartnered program with Sanwa Kagaku Kenkyusho in Japan for Paltusotine.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial metrics supporting organizational capacity and investment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and investments as of September 30, 2025: $1.1 billion.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash used in operations for 2025: Between $340 million and $370 million.\u003c\/li\u003e\n\u003cli\u003eReimbursement rate for filled Paltusotine prescriptions: Approximately 50% as of November 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 4. Nonpeptide Drug Conjugate (NDC) Platform Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers a novel, potentially first-in-class approach to selectively target tumors (like SST2-expressing NETs) by delivering a potent payload (MMAE). CRN09682 is the first candidate. The initiation of the Phase 1\/2 trial for CRN09682 in Q4 2025 demonstrates value realization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. A proprietary, validated platform technology that yields clinical candidates is rare in the industry. The NDC technology is developed in-house.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. The specific chemistry, linkers, and know-how behind the NDC platform are proprietary and difficult to reverse-engineer. The manufacturing utilizes traditional chemical synthesis methods, avoiding the complex and heterogeneous methods of most antibody-drug conjugates.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. They are executing by starting the Phase 1\/2 trial for CRN09682, showing they can operationalize the platform. The company reported $1.2 billion in cash, cash equivalents, and investments as of June 30, 2025, anticipated to provide runway into 2029.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Platform technologies, if proven, offer a repeatable engine for future drug discovery. Research and development expenses for the three months ended June 30, 2025, were $80.3 million.\u003c\/p\u003e\n\u003cp\u003eKey statistical and financial metrics related to the NDC platform and operational capacity:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Candidate\u003c\/td\u003e\n\u003ctd\u003eCRN09682\u003c\/td\u003e\n\u003ctd\u003eNonpeptide Drug Conjugate (NDC)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayload Delivered\u003c\/td\u003e\n\u003ctd\u003eMonomethyl Auristatin E (MMAE)\u003c\/td\u003e\n\u003ctd\u003eCytotoxic payload for SST2-expressing tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1\/2 Trial Initiation\u003c\/td\u003e\n\u003ctd\u003eFourth Quarter of 2025\u003c\/td\u003e\n\u003ctd\u003eDosing of first patient announced on December 3, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Enrollment (Total)\u003c\/td\u003e\n\u003ctd\u003eUp to 150 participants\u003c\/td\u003e\n\u003ctd\u003eAcross Phase 1 and Phase 2 of the CRN09682 study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e$1.2 billion\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents, and investments as of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Projection\u003c\/td\u003e\n\u003ctd\u003eInto 2029\u003c\/td\u003e\n\u003ctd\u003eBased on current projections as of August 7, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e$90.5 million\u003c\/td\u003e\n\u003ctd\u003eFor the quarter ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe NDC platform is designed to leverage a small molecule G protein coupled receptor (GPCR) ligand instead of an antibody, which avoids the complex manufacturing methods required for antibody drug conjugates.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe NDC approach is intended to enhance tumor penetration and intracellularly release a potent anti-tumor agent, while minimizing systemic exposure and associated toxicities.\u003c\/li\u003e\n\u003cli\u003eCRN09682 is designed to bind selectively and with high potency to SST2-expressing tumor cells.\u003c\/li\u003e\n\u003cli\u003eThe company's total assets were reported as US$1.4 billion in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 5. Expertise in GPCR Small Molecule Drug Discovery\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Foundational scientific skill creating paltusotine and other pipeline assets. Allows for the creation of orally delivered, small-molecule therapeutics targeting G-protein coupled receptors (GPCRs).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies target GPCRs, but Crinetics has a proven track record of success in this specific, complex area of endocrinology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Relies on deep, institutional knowledge and the specific talent of their scientific founders and team.\u003c\/p\u003e\n\u003cp\u003e\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003cp\u003eThis expertise underpins the entire R\u0026amp;D function, which saw \u003cstrong\u003e$90.5 million\u003c\/strong\u003e in R\u0026amp;D spend in Q3 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$90.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$61.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisclosed Pipeline Programs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Pipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Product Approval Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 25, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePalsonify (paltusotine) U.S. FDA Approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003ch\u003e\u003ch\u003ePipeline Assets Stemming from Expertise\u003c\/h\u003e\u003c\/h\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePalsonify (paltusotine): First once-daily, oral treatment approved by the U.S. FDA for adults with acromegaly.\u003c\/li\u003e\n\u003cli\u003eAtumelnant: Late-stage investigational candidate for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.\u003c\/li\u003e\n\u003cli\u003eCRN09682: First candidate from the Nonpeptide Drug Conjugate (NDC) platform, in a Phase 1\/2 study for SST2-expressing solid tumors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Scientific talent and institutional knowledge are very hard for competitors to poach or build quickly.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 6. Late-Stage Atumelnant Development (CAH\/Cushing's)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positions the company to potentially offer a best-in-class oral treatment for Congenital Adrenal Hyperplasia (CAH) by normalizing androstenedione levels, setting a new standard of care. The Phase 3 CALM-CAH study primary endpoint is designed to demonstrate atumelnant's potential ability to normalize androstenedione (A4) levels with \u003cstrong\u003ephysiologic\u003c\/strong\u003e glucocorticoid (GC) replacement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Atumelnant is the \u003cstrong\u003efirst and only\u003c\/strong\u003e small molecule ACTH receptor antagonist in clinical development, acting selectively at the melanocortin type 2 receptor (MC2R). The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant in the treatment of classic CAH.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. The specific compound and its clinical data are proprietary. Phase 2 TouCAHn trial data demonstrated compelling treatment benefits.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eResult\/Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean Androstenedione (A4) Reduction (Up to)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Trial Enrollment (TouCAHn)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e28\u003c\/strong\u003e adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses Tested in Phase 2\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40 mg, 80 mg, 120 mg\u003c\/strong\u003e once daily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTestosterone Normalization (Female Participants)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8 of 13\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResumption of Menses\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAndrogen-Mediated Polycythemia Resolution\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5 of 6\u003c\/strong\u003e impacted participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are initiating pivotal Phase 3 trials, showing commitment to this asset. The company maintains a strong financial position to support these efforts.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitiation of the CALM-CAH Phase 3 study in adults and the BALANCE-CAH Phase 2\/3 study in pediatrics is expected in the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and investments totaled \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash used in operations for 2025 is between \u003cstrong\u003e$340 and $370 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCurrent cash position is expected to fund the operating plan into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization as of December 3, 2025, was \u003cstrong\u003e$4.27 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Success hinges on Phase 3 data, but if positive, it grants a significant lead in a rare disease market as the first-in-class oral ACTH receptor antagonist.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 7. Established Commercialization Infrastructure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for the rapid and effective delivery of PALSONIFY™ to patients post-approval, maximizing the initial market opportunity. They have 'nearly completed the build-out of a premier commercial organization' as of June 30, 2025.\u003c\/p\u003e\n\u003ch5\u003eValue Metrics\u003c\/h5\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePALSONIFY Approval Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 25, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected PALSONIFY Sales by 2034\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many clinical-stage biotechs lack this infrastructure until late in the game.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building a specialized sales, marketing, and medical affairs team takes time and significant SG\u0026amp;A investment, which they have made.\u003c\/p\u003e\n\u003ch5\u003eImitability Investment Data\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eSG\u0026amp;A expenses for the quarter ended September 30, 2025: \u003cstrong\u003e$52.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A expenses for the quarter ended September 30, 2024: \u003cstrong\u003e$25.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A expenses for Q1 FY2025: \u003cstrong\u003e$35.5 million\u003c\/strong\u003e, a \u003cstrong\u003e71%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The seamless launch execution post-September 25, 2025 approval demonstrates organizational readiness. The launch was described as 'off to a very good start.'\u003c\/p\u003e\n\u003ch5\u003eOrganizational Financial Context\u003c\/h5\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Measure\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Investments (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Cash Used in Operations (2025 Guidance)\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e$340 and $370 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Projection\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While costly to build, a commercial team can be replicated over time by well-funded rivals.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 8. Strategic International Partnership (SKK for Paltusotine)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eAmount\/Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment Received\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$13.0 million\u003c\/strong\u003e (nonrefundable)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eUp to an additional \u003cstrong\u003e$25.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales-Based Payments\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTiered royalties\u003c\/strong\u003e upon market approval in Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Cost Responsibility (Japan)\u003c\/td\u003e\n\u003ctd\u003eSKK assumes \u003cstrong\u003eall costs\u003c\/strong\u003e for clinical trials and regulatory applications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Market Size (Japan)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e10,000\u003c\/strong\u003e acromegaly patients and \u003cstrong\u003e11,000\u003c\/strong\u003e NETs patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSecuring a partnership with a major Japanese entity for a lead asset represents a specific, valuable arrangement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific terms and relationship with SKK are unique to Crinetics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePartnership structure is integrated into revenue reporting, as evidenced by licensing revenues.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2023 Revenues: Derived from the paltusotine licensing arrangement with SKK.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 Revenues: \u003cstrong\u003e$1.0 million\u003c\/strong\u003e, primarily from the SKK agreement.\u003c\/li\u003e\n\u003cli\u003eQ3 2024 Revenues: \u003cstrong\u003e$0.3 million\u003c\/strong\u003e, derived from the licensing arrangement.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Revenues: \u003cstrong\u003e$1.0 million\u003c\/strong\u003e, derived from licensing and supply agreements.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenues: \u003cstrong\u003e$0.1 million\u003c\/strong\u003e, all derived from the SKK licensing agreement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe partnership de-risks international expansion and provides a steady revenue stream, including the initial \u003cstrong\u003e$13.0 million\u003c\/strong\u003e upfront payment.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCrinetics Pharmaceuticals, Inc. (CRNX) - VRIO Analysis: 9. Demonstrated Clinical Efficacy and Patient Preference Data (Paltusotine)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides strong evidence supporting the drug's superiority over existing treatments, which drives physician adoption and payer coverage. \u003cstrong\u003e87%\u003c\/strong\u003e of patients preferred paltusotine over prior injectable therapy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Quantifiable, high-preference data against the standard of care is the gold standard for adoption.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This specific data set is owned by Crinetics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are actively using this data to drive reimbursement, with about \u003cstrong\u003e50%\u003c\/strong\u003e of filled prescriptions reimbursed as of Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Strong clinical data is the ultimate barrier to entry in pharma.\u003c\/p\u003e\n\u003cp\u003eThe clinical data package for Paltusotine (PALSONIFY™) demonstrates significant efficacy, particularly in comparison to existing injectable somatostatin receptor ligand (SRL) therapies, which typically achieve disease control in about \u003cstrong\u003e20%\u003c\/strong\u003e to \u003cstrong\u003e40%\u003c\/strong\u003e of patients. The data supports the drug's profile as a preferred alternative, especially given the burden of recurring injections associated with the standard of care.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial\/Metric\u003c\/th\u003e\n\u003cth\u003eComparator\/Context\u003c\/th\u003e\n\u003cth\u003eEfficacy Endpoint\u003c\/th\u003e\n\u003cth\u003eResult\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePATHFNDR-1 (Switch)\u003c\/td\u003e\n\u003ctd\u003eMaintained IGF-1 $\\le 1.0\\text{x ULN}$ at 36 weeks\u003c\/td\u003e\n\u003ctd\u003ePaltusotine vs. Placebo\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e83%\u003c\/strong\u003e vs. \u003cstrong\u003e4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePATHFNDR-1 (Switch)\u003c\/td\u003e\n\u003ctd\u003eMaintained $\\text{GH levels } \u0026lt; 1.0\\text{ ng\/mL}$ at 36 weeks\u003c\/td\u003e\n\u003ctd\u003ePaltusotine vs. Placebo\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e87%\u003c\/strong\u003e vs. \u003cstrong\u003e18%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePATHFNDR-2 (Treatment-Naïve)\u003c\/td\u003e\n\u003ctd\u003eAchieved IGF-1 $\\le \\text{ULN}$ at 24 weeks\u003c\/td\u003e\n\u003ctd\u003ePaltusotine vs. Placebo\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e56%\u003c\/strong\u003e vs. \u003cstrong\u003e5%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Switch Maintenance\u003c\/td\u003e\n\u003ctd\u003eAchieved IGF-I levels within \u003cstrong\u003e20%\u003c\/strong\u003e of baseline or lower at Week 13 (Switched from SRLs)\u003c\/td\u003e\n\u003ctd\u003ePaltusotine vs. SRL Baseline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe data supports the drug's ability to provide reliable, durable control, with investigator-assessed progression-free survival rate of \u003cstrong\u003e74%\u003c\/strong\u003e following one year of treatment in a neuroendocrine tumor study.\u003c\/p\u003e\n\u003cp\u003eFinancial and Reimbursement Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReimbursement: Approximately \u003cstrong\u003e50%\u003c\/strong\u003e of filled prescriptions reimbursed as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eCash Position (Q3 2025): Cash, cash equivalents, and investments totaled \u003cstrong\u003e\\$1.1 billion\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eCash Burn Guidance (2025): Anticipated cash used in operations to be between \u003cstrong\u003e\\$340\u003c\/strong\u003e and \u003cstrong\u003e\\$370 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Runway Projection: Expected to fund current operating plan into \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Financials: Net loss of \u003cstrong\u003e\\$130.1 million\u003c\/strong\u003e; Free Cash Flow of \u003cstrong\u003e$-\\text{111.58M}$\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: Draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516144869525,"sku":"crnx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/crnx-vrio-analysis.png?v=1740164176","url":"https:\/\/dcf-model.com\/fr\/products\/crnx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}